Prostate Cancer News & Features

The researchers found that very few patients who chose active surveillance actually received the recommended monitoring, one of the study authors said.

Two drugs that interfere with cancer's ability to use testosterone for fuel, apalutamide (Erleada) and enzalutamide (Xtandi), are already approved for use against more advanced prostate tumors that don't respond to regular therapy.

Changes in chromosomes within prostate cancer cells may help predict how aggressive a tumor is, a new study has found.

The effect was found only with atenolol (Tenormin). Two other beta blockers -- metoprolol (Lopressor/Toprol XL) and carvedilol (Coreg) -- did not appear to provide any protection against prostate cancer.

High-dose radiation could be more convenient for low-risk patients, and less time-consuming and costly for the medical system.

Of the 44 countries studied, prostate cancer rates rose in four and fell in seven. The United States had the biggest decrease. Rates remained stable in the 33 other countries.

Any potential benefit from low-dose aspirin needs to be weighed against the risk of gastrointestinal bleeding linked with its use, researchers said.

Over just five years, researchers found, the number of men who opted for monitoring tripled -- from 14 percent of patients in 2010, to 42 percent in 2015.

The newly released long-term data show that the reduction of prostate cancer risk has continued and that fewer than 100 men in the study of nearly 19,000 died from prostate cancer in more than two decades of follow-up.

A new study that followed men with larger and more aggressive prostate cancer than is usually diagnosed today found that those who had surgery instead of “watchful waiting” lived a few years longer.

Compared to non-drinkers, men who reported having at least one alcoholic drink a day between ages 15 and 19 had more than triple the odds of developing aggressive prostate cancer in adulthood, the researchers said.

Overall, cancer diagnoses and cancer deaths continue to decline in the United States, said lead author Kathleen Cronin, a researcher with the U.S. National Cancer Institute.

New report says prostate cancer screening may make sense for some men between the ages of 55 and 69, including those at higher than average risk because of a family history of prostate or related cancers or because they are African American

Half of the men took part in a 12-week exercise and nutrition program, while the other half received only basic education about their diagnosis and about exercise.

While the impact of prostate cancer and its treatment on men has been widely studied, there has been little examination of how patients' partners are affected, the association noted.

Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows.

Analysis of 2 major trials on the prostate cancer screen shows it cuts men's risk of dying from the disease

Hormone-suppressing regimen may raise odds for heart failure, but it brings benefits, too, researchers say

20-year study found little difference in death rates, more complications with surgery

Findings could 'change clinical practice overnight,' leading oncologist says

New study suggests the disease progresses faster for them

Study suggests the ancient practice might ease side effects of therapy

Men aged 55 to 69 should discuss PSA blood screen with their doctor, expert panel recommends

Even 'active surveillance' may have risks, such as anxiety

Find out how exercise can help manage treatment side effects and boost your mood when you have prostate cancer.